-
公开(公告)号：US20130123273A1
公开(公告)日：2013-05-16
申请号：US13807816
申请日：2011-07-04
申请人： Guohua Pan , Jacqueline M. Mason , Xin Wei , Miklos Feher
发明人： Guohua Pan , Jacqueline M. Mason , Xin Wei , Miklos Feher
IPC分类号： A61K31/495 , A61K31/4439 , A61K31/416
CPC分类号： A61K31/416 , A61K31/4439 , A61K31/495 , A61K31/496 , A61K31/497 , A61K31/5377
摘要： Provided herein are methods, uses and compositions for treating a patient with cancer wherein the cancer is characterized by a PTEN gene mutation. In particular embodiments, the methods comprise administering to the patient a composition comprising a therapeutically effective amount of a PLK4 antagonist, and identifying a patient that is likely to be responsive to PLK4 antagonist therapy, if PTEN gene mutation is present.
摘要翻译： 本文提供了用于治疗癌症患者的方法，用途和组合物，其中癌症的特征在于PTEN基因突变。 在具体实施方案中，所述方法包括向患者施用包含治疗有效量的PLK4拮抗剂的组合物，并且如果存在PTEN基因突变，则鉴定可能对PLK4拮抗剂治疗有反应的患者。
-
公开(公告)号：US08933070B2
公开(公告)日：2015-01-13
申请号：US13807816
申请日：2011-07-04
申请人： Guohua Pan , Jacqueline M. Mason , Xin Wei , Miklos Feher
发明人： Guohua Pan , Jacqueline M. Mason , Xin Wei , Miklos Feher
IPC分类号： A61K31/553 , A61K31/00 , A61K31/535 , C07D273/00 , C07D211/00 , A61K31/495 , A61K31/416 , A61K31/4439 , A61K31/497
CPC分类号： A61K31/416 , A61K31/4439 , A61K31/495 , A61K31/496 , A61K31/497 , A61K31/5377
摘要： Provided herein are methods, uses and compositions for treating a patient with cancer wherein the cancer is characterized by a PTEN gene mutation. In particular embodiments, the methods comprise administering to the patient a composition comprising a therapeutically effective amount of a PLK4 antagonist, and identifying a patient that is likely to be responsive to PLK4 antagonist therapy, if PTEN gene mutation is present.
摘要翻译： 本文提供了用于治疗癌症患者的方法，用途和组合物，其中癌症的特征在于PTEN基因突变。 在具体实施方案中，所述方法包括向患者施用包含治疗有效量的PLK4拮抗剂的组合物，并且如果存在PTEN基因突变，则鉴定可能对PLK4拮抗剂治疗有反应的患者。
-
公开(公告)号：US08481533B2
公开(公告)日：2013-07-09
申请号：US13529542
申请日：2012-06-21
申请人： Peter B. Sampson , Yong Liu , Sze-Wan Li , Bryan T. Forrest , Heinz W. Pauls , Louise G. Edwards , Miklos Feher , Narendra Kumar B. Patel , Radoslaw Laufer , Guohua Pan
发明人： Peter B. Sampson , Yong Liu , Sze-Wan Li , Bryan T. Forrest , Heinz W. Pauls , Louise G. Edwards , Miklos Feher , Narendra Kumar B. Patel , Radoslaw Laufer , Guohua Pan
IPC分类号： A61K31/5377 , A61K31/416 , C07D273/01 , C07D231/54
CPC分类号： C07D403/10 , A61K31/5377 , A61K45/06 , C07D231/56 , C07D403/04 , C07D403/14 , C07D413/14
摘要： The invention is directed to a compound represented by the following structural formula and pharmaceutically acceptable salts thereof: Compounds represented by this structural formula are kinase inhibitors and are therefore disclosed herein for the treatment of cancer. Definitions for the variables in the structural formula are provided herein.
-
公开(公告)号：US20110263598A1
公开(公告)日：2011-10-27
申请号：US13081254
申请日：2011-04-06
申请人： Peter B. Sampson , Yong Liu , Sze-Wan Li , Bryan T. Forrest , Heinz W. Pauls , Louise G. Edwards , Miklos Feher , Narendra Kumar B. Patel , Radoslaw Laufer , Guohua Pan
发明人： Peter B. Sampson , Yong Liu , Sze-Wan Li , Bryan T. Forrest , Heinz W. Pauls , Louise G. Edwards , Miklos Feher , Narendra Kumar B. Patel , Radoslaw Laufer , Guohua Pan
IPC分类号： A61K31/5377 , A61P35/02 , A61K31/416 , A61P35/00 , C07D487/04 , C07D273/01
CPC分类号： C07D403/10 , A61K31/5377 , A61K45/06 , C07D231/56 , C07D403/04 , C07D403/14 , C07D413/14
摘要： The invention is directed to a compound represented by the following structural formula and pharmaceutically acceptable salts thereof: Compounds represented by this structural formula are kinase inhibitors and are therefore disclosed herein for the treatment of cancer. Definitions for the variables in the structural formula are provided herein.
摘要翻译： 本发明涉及由以下结构式表示的化合物及其药学上可接受的盐：由该结构式表示的化合物是激酶抑制剂，因此本文公开了用于治疗癌症的化合物。 本文提供了结构式中变量的定义。
-
5.发明授权Indazolyl, benzimidazolyl, benzotriazolyl substituted indolinone derivatives as kinase inhibitors useful in the treatment of cancer 有权吲唑基，苯并咪唑基，苯并三唑基取代的二氢吲哚酮衍生物作为可用于治疗癌症的激酶抑制剂公开(公告)号：US08765748B2
公开(公告)日：2014-07-01
申请号：US12808961
申请日：2008-12-19
申请人： Heinz W. Pauls , Bryan T. Forrest , Radoslaw Laufer , Miklos Feher , Peter Brent Sampson , Guohua Pan , Sze-Wan Li , Yong Liu
发明人： Heinz W. Pauls , Bryan T. Forrest , Radoslaw Laufer , Miklos Feher , Peter Brent Sampson , Guohua Pan , Sze-Wan Li , Yong Liu
IPC分类号： A61P35/00 , A61P35/02 , C07D401/14 , C07D403/06 , C07D403/12 , C07D403/10 , C07D403/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/04 , A61K31/416 , A61K31/4192 , A61K31/4184 , A61K31/4439 , A61K31/496 , A61K31/437 , A61K31/5377
CPC分类号： C07D403/06 , C07D401/14 , C07D403/12 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/04
摘要： The present invention is directed to a compound is represented by Structural Formula (A): or a pharmaceutically acceptable salt thereof. The present invention is also directed to a pharmaceutical composition comprising a compound represented by Structural Formula (A) described above or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent. Also disclosed is a method of treating a subject having cancer, wherein the method comprises administering a therapeutically effective amount of a compound represented by Structural Formula (A) described above or a pharmaceutically acceptable salt thereof.
摘要翻译： 本发明涉及由结构式（A）表示的化合物或其药学上可接受的盐。 本发明还涉及包含由上述结构式（A）表示的化合物或其药学上可接受的盐和药学上可接受的载体或稀释剂的药物组合物。 还公开了治疗患有癌症的受试者的方法，其中所述方法包括施用治疗有效量的由上述结构式（A）表示的化合物或其药学上可接受的盐。
-
6.发明授权公开(公告)号：US08680282B2
公开(公告)日：2014-03-25
申请号：US12671154
申请日：2008-08-01
申请人： Heinz W. Pauls , Bryan T. Forrest , Peter Brent Sampson , Yong Liu , Radoslaw Laufer , Yunhui Lang , Miklos Feher , Yi Yao , Guohua Pan
发明人： Heinz W. Pauls , Bryan T. Forrest , Peter Brent Sampson , Yong Liu , Radoslaw Laufer , Yunhui Lang , Miklos Feher , Yi Yao , Guohua Pan
IPC分类号： C07D211/58 , A61K31/4468
CPC分类号： C07D211/58 , C07C275/36 , C07D205/04 , C07D207/09 , C07D211/56 , C07D405/12
摘要： A CPT1 inhibitor compound is represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof: or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject having cancer comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.
摘要翻译： CPT1抑制剂化合物由结构式（I）或其药学上可接受的盐表示：或其药学上可接受的盐。 药物组合物包含由结构式（I）表示的化合物或其药学上可接受的盐。 治疗患有癌症的受试者的方法包括向受试者施用治疗有效量的由结构式（I）表示的化合物或其药学上可接受的盐。
-
7.发明申请INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER 有权CARNITINE PALMITOYLTRANSFERASE和治疗癌症的抑制剂公开(公告)号：US20100105900A1
公开(公告)日：2010-04-29
申请号：US12530429
申请日：2008-03-09
申请人： Heinz W. Pauls , Peter Brent Sampson , Bryan T. Forrest , Radoslaw Laufer , Yong Liu , Miklos Feher , Yi Yao , Guohua Pan
发明人： Heinz W. Pauls , Peter Brent Sampson , Bryan T. Forrest , Radoslaw Laufer , Yong Liu , Miklos Feher , Yi Yao , Guohua Pan
IPC分类号： C07D295/18 , C07D307/02 , C07D333/22 , C07C229/00 , C07D239/02 , C07D213/78 , C07D417/04
CPC分类号： C07D409/06 , C07C1/26 , C07C17/10 , C07C2529/40 , C07D207/325 , C07D213/71 , C07D213/82 , C07D231/12 , C07D231/14 , C07D263/34 , C07D277/48 , C07D295/215 , C07D307/24 , C07D307/68 , C07D307/82 , C07D333/34 , C07D333/40 , C07D401/04 , C07D405/06 , C07D409/04 , C07D413/04 , C07D413/06 , C07D417/04 , C07C9/00 , C07C19/075
摘要： A CPT inhibitor compound is represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof: or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject having cancer comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.
摘要翻译： CPT抑制剂化合物由结构式（I）或其药学上可接受的盐表示：或其药学上可接受的盐。 药物组合物包含由结构式（I）表示的化合物或其药学上可接受的盐。 治疗患有癌症的受试者的方法包括向受试者施用治疗有效量的由结构式（I）表示的化合物或其药学上可接受的盐。
-
公开(公告)号：US20120149686A1
公开(公告)日：2012-06-14
申请号：US13262888
申请日：2010-04-06
申请人： Peter B. Sampson , Yong liu , Sze-Wan Le , Brian T. Forrest , Heinz W. Pauls , Louise G. Edwards , Miklos Feher , Narendra Kumar B. Patel , Guohua Pan
发明人： Peter B. Sampson , Yong liu , Sze-Wan Le , Brian T. Forrest , Heinz W. Pauls , Louise G. Edwards , Miklos Feher , Narendra Kumar B. Patel , Guohua Pan
IPC分类号： A61K31/416 , C07D471/10 , A61K31/437 , C07D401/14 , A61P35/02 , C07D413/14 , A61K31/5377 , A61K31/553 , A61P35/00 , C07D403/10 , A61K31/496
CPC分类号： A61K31/553 , A61K31/416 , A61K31/437 , A61K31/496 , A61K31/5377 , A61K45/06 , C07D401/14 , C07D403/04 , C07D403/14 , C07D409/14 , C07D413/14 , C07D471/04 , C07D471/10
摘要： The invention is directed to a compound represented by the following structural formula and pharmaceutically acceptable salts thereof: Compounds represented by this structural formula are kinase inhibitors and are therefore disclosed herein for the treatment of cancer. Definitions for the variables in the structural formula are provided herein.
摘要翻译： 本发明涉及由以下结构式表示的化合物及其药学上可接受的盐：由该结构式表示的化合物是激酶抑制剂，因此本文公开了用于治疗癌症的化合物。 本文提供了结构式中变量的定义。
-
9.发明申请INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER 有权辛唑，苯并咪唑，苯并三唑取代的吲哚啉酮衍生物作为激素治疗癌症中的激素抑制剂公开(公告)号：US20110065702A1
公开(公告)日：2011-03-17
申请号：US12808961
申请日：2008-12-19
申请人： Heinz W. Pauls , Bryan T. Forrest , Radoslaw Laufer , Miklos Feher , Peter Brent Sampson , Guohua Pan , Sze-Wan Li , Yong Liu
发明人： Heinz W. Pauls , Bryan T. Forrest , Radoslaw Laufer , Miklos Feher , Peter Brent Sampson , Guohua Pan , Sze-Wan Li , Yong Liu
IPC分类号： A61K31/416 , C07D403/10 , C07D403/14 , C07D471/04 , C07D413/14 , A61K31/4192 , A61K31/4184 , A61K31/4439 , A61K31/496 , A61K31/437 , A61K31/5377 , A61P35/00 , A61P35/02
CPC分类号： C07D403/06 , C07D401/14 , C07D403/12 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/04
摘要： The present invention is directed to a compound is represented by Structural Formula (A):or a pharmaceutically acceptable salt therof. The present invention is also directed to a pharmaceutical composition comprising a compound represented by Structural Formula (A) described above or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent. Also disclosed is a method of treating a subject having cancer, wherein the method comprises administering a therapeutically effective amount of a compound represented by Structural Formula (A) described above or a pharmaceutically acceptable salt thereof.
摘要翻译： 本发明涉及由结构式（A）表示的化合物或其药学上可接受的盐。 本发明还涉及包含由上述结构式（A）表示的化合物或其药学上可接受的盐和药学上可接受的载体或稀释剂的药物组合物。 还公开了治疗患有癌症的受试者的方法，其中所述方法包括施用治疗有效量的由上述结构式（A）表示的化合物或其药学上可接受的盐。
-
公开(公告)号：US08481525B2
公开(公告)日：2013-07-09
申请号：US13262888
申请日：2010-04-06
申请人： Peter Brent Sampson , Yong Liu , Sze-Wan Li , Bryan T. Forrest , Heinz W. Pauls , Louise G. Edwards , Miklos Feher , Narendra Kumar B. Patel , Guohua Pan
发明人： Peter Brent Sampson , Yong Liu , Sze-Wan Li , Bryan T. Forrest , Heinz W. Pauls , Louise G. Edwards , Miklos Feher , Narendra Kumar B. Patel , Guohua Pan
IPC分类号： A61K31/55 , A61K31/5377 , A61K31/496 , A61K31/4427 , A61K31/416 , C07D223/14 , C07D273/00 , C07D237/02 , C07D215/00 , C07D231/54
CPC分类号： A61K31/553 , A61K31/416 , A61K31/437 , A61K31/496 , A61K31/5377 , A61K45/06 , C07D401/14 , C07D403/04 , C07D403/14 , C07D409/14 , C07D413/14 , C07D471/04 , C07D471/10
摘要： The invention is directed to a compound represented by the following structural formula and pharmaceutically acceptable salts thereof: Compounds represented by this structural formula are kinase inhibitors and are therefore disclosed herein for the treatment of cancer. Definitions for the variables in the structural formula are provided herein.
-
-
-
-
-
-
-
-
-
搜索结果
39 条记录 (耗时 0.041 秒)
